SCPH has been in the news 750% more than usual
Aug 12, 2024, 2:32 PM
10.98%
What does SCPH do
scPharmaceuticals, Inc., based in Burlington, Massachusetts, focuses on developing subcutaneous pharmaceutical products like FUROSCIX for conditions such as congestive heart failure and infection treatments. The company, founded with 96 employees, went public in 2017 and prioritizes healthcare cost reduction and improved health outcomes.
SCPH has been in the news recently: scPharmaceuticals, Inc. has announced a proposed underwritten public offering of 12 million shares at a price of $4.00 each, with the potential for underwriters to purchase an additional 15% within 30 days. The company also received FDA approval to expand FUROSCIX indications for treating congestion in about 10% of Class IV chronic heart failure patients.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.